Blockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
Eli Lilly is lowering the cost of its blockbuster weight loss drug. Kamala Harris’ campaign criticizes Trump on fiscal responsibility. And a new study finds living among trees is beneficial to heart health. Here’s what to know today. Eli Lilly announces lower price of blockbuster weight loss drug Eli Lilly announced today that it would lower the cost of its weight loss drug, Zepbound, in an effort to get the medicine in the hands of more people and ease supply constraints.
Similar scenes took place in the capital, Kyiv, in the southern city of Odesa and others across the country, Ukrainian president Volodymyr Zelenskyy said on Telegram. It was Moscow’s most intense strike in weeks. Yet after two years of war, Ukrainians seem to have grown resilient to this type of attack. Videos and comments on social media, as well as statements from officials, paint a picture of how the day played out.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Weight Loss Drug Zepbound Could Lower Heart Failure Risks, Eli Lilly SaysTy Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
続きを読む »
Zepbound price cut: Eli Lilly lowers cost of weight loss drugBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
続きを読む »
Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage studyThe data adds to mounting evidence that Zepbound and other popular GLP-1 drugs have health benefits beyond promoting weight loss and regulating blood sugar.
続きを読む »
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
続きを読む »
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
続きを読む »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
続きを読む »